Novo Nordisk (NVO.N) shares fell about 3% in pre-market trading after its UBT251 weight loss drug trial showed a 19.7% weight loss effect.

2026-02-24

Novo Nordisk (NVO.N) shares fell about 3% in pre-market trading after its UBT251 weight loss drug trial showed a 19.7% weight loss effect.